GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oscotec 039200.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

36,150

-0.41%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Oscotec

Its shares trade on KOSDAQ under the ticker 039200.KQ. It has been listed since 17 January 2007. In the fiscal year to 31 December 2025, it reported revenue of ₩99.84bn and net income of ₩52.34bn. At that date it held total assets of ₩229.85bn and shareholders' equity of ₩181.31bn.

Oscotec, Inc. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2007-01-17. The firm operates its business through three divisions: new medicines division, functional material products division and dental bone graft division. Its new medicines division provides osteoporosis drugs, arthritis drugs and periodontal disease drugs. Its functional material products division provides functional materials and food used for promoting bone growth and periodontal health. Its dental bone graft division provides bone graft materials, membranes and centrifuges. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
17 Jan 2007
Website
oscotec.com ↗

Leadership

Pay as last reported

  • Mr. Se Won KimPresident
  • Mr. Jeong Geun KimCo-Chief Executive Officer, Director, since 2020
  • Mr. Tae Yeong YoonCo-Chief Executive Officer, Director, since 2020
  • Mr. Sang Hyeon LeeManaging Director, since 2021
  • Mr. Yun Tae KimManaging Director
  • Mr. Chang Nam KimInternal Auditor

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seongnam, Gyeonggi-Do, South Korea
  • Operates through three divisions: new medicines, functional materials, and dental bone graft
  • Offers a range of pharmaceutical products including osteoporosis, arthritis, and periodontal disease drugs

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No information on competitive advantages or unique selling points

Opportunities

  • Expanding domestic and overseas market distribution for pharmaceutical products
  • Potential growth in functional materials and food products for bone and periodontal health
  • Opportunity to increase market presence in the pharmaceutical sector

Threats

  • No specific threats mentioned in the provided information
  • No details on market competition or regulatory challenges
  • No information on potential risks to business operations

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.